117 posts categorized "Expert Commentary"


Philadelphia Inquirer: Pharmacists are on the front lines of the opioid crisis. So why don’t more fight?

Dan Ventricelli, assistant professor of pharmacy, was quoted in a column from the Philadelphia Inquirer’s Mike Newall reacting to a story that highlighted that most pharmacies in Philadelphia don’t carry Naloxone.
"At the end of the day, just having it available doesn't mean it’s being utilized," Ventricelli said. "The next step is providing further education to pharmacists to help them identify who would be good candidates for needing it or someone would be in a good position to help someone with it."


CBS3: USciences Gets Moving to Fight Breast Cancer

Dr. Isabelle Mercier organized a workout class in honor of Breast Cancer Awareness Month to bring the issue to the forefront for our students and show how exercise can reduce the risk of breast cancer or extend the lives of those suffering from the disease. A representative from the Susan G Komen organization attended our event and it was featured on CBS 3 Philly. This was a collaboration between our scientists and the office of student life’s campus recreation staff. A good time was had by all.     


WHYY: With $1M state grant, Temple to address need for addiction meds in Philadelphia

Temple University’s health system will use a $1 million grant from the state of Pennsylvania to expand access to state-of-the-art addiction treatment under a program that aims to make it easier to get medications such as buprenorphine — also known under the brand name Suboxone, WHYY reported. Gail Groves Scott, manager of the Substance Use Disorders Institute at University of the Sciences, said Temple’s grant would help fill an unmet need for buprenorphine treatment in Philadelphia.  


Philadelphia Inquirer: Want to break into Philly’s booming craft beer scene? Study up.

The Philadelphia Inquirer and Daily News profiled USciences’ Brewing Science Program, which three years since its founding is preparing students to the business of craft brewing which has grown in the region in the past few years. The article highlights the success of program alumni, how it is keeping up with industry trends and a pending patent for a yeast which brews sour beer.   


Alumna Co-Authored Article for Contract Pharma Mag

USciences alumna Elena Mack MB’98 co-authored an article for Contract Pharma Magazine titled “Fostering Global Regulatory Collaboration in the Marketing of Combination Products” about how early partnerships between pharmaceutical companies and drug delivery technology providers can be valuable.


Managed Markets: Home-based care: A blast from the past might be health care’s future

Harman Kaur PharmD’18 authored an article for Managed Markets about the resurgence of home-based care in the 21st Century insurance works to provide care to homebound individuals.    


Health Day: Vaccination 101: Make Sure Kids Are Up to Date

USciences’ Zachary Klase PhD asked all parents to make sure their children are up to date on vaccines before they head back to school. Dr. Klase’s health tip was featured on Health Day.  


Philly.com: Opioid approvals should protect public health

Gail Groves Scott and Daniel Ventricelli penned a commentary for Philly.com about how recent actions by federal and state actions against producers of opioids, have paved the way for a new thinking behind FDA approvals to give greater consideration to population health.


The Outline: The Latest Dangerous Drug Trend Doesn't Actually Exist

Gail Groves Scott was quoted in a story from The Outline about “Narcan parties,” which law enforcement refer although few people have any evidence that they have ever happened.


Philadelphia Inquirer: New on the streets: Drug for nerve pain boosts high for opioid abusers

The Philadelphia Inquirer interviewed Gail Goves Scott, manager of the University of the Sciences’ new Center for Substance Use Disorders about the recent news that individuals are have begun abusing gabapentin, a non-opioid medication used to treat nerve pain.  
“I was surprised to hear from counselors and criminal justice folks at conferences this year that gabapentin was being abused,” said Gail Groves Scott, manager of Philadelphia’s University of the Sciences Center for Substance Use Disorders. “It was news to me.” 
“I used to work as a pharma rep in pain management and I never heard a doctor say it was being abused. It’s a well-known non-opioid choice for patients with neuropathic pain,” she said. “I think it’s well-known that people with a disease of addiction will use whatever they can get, even if the effect is only psychological.”